Plasmid DNA CDMOs with Clean FDA Inspection History

· updated as new inspection, certificate, and trial data enters the platform
13
CDMOs tracked
13
Fully scored
9
With FDA records
41
FDA inspections
78
EMA/MHRA GMP certs

Plasmid DNA is the upstream starting material for viral vectors, mRNA, and DNA therapeutics — which makes plasmid supply a frequent bottleneck for the entire advanced-therapy pipeline. Plasmid CDMOs run microbial (E. coli) fermentation, alkaline lysis, and chromatographic purification to GMP grade.

Selecting a plasmid CDMO turns on GMP vs research grade, supercoiled fraction and purity, fermentation scale, and lead time. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 19 NAI (no action), 22 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (29), UNITED KINGDOM (24), Germany (23), Austria (12), France (7).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
3
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
4
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
5
WK
Jena, DE · Amsterdam, NL · San Diego, CA
82.9 100.0 1 insp · 13 GMP 2023-12-07 · VAI — —
6
RB
Hamburg, Germany
82.9 100.0 0 insp · 9 GMP None on file — —
7
KE
Seraing, BE
81.6 99.9 1 insp · 4 GMP 2024-02-26 · VAI — —
8
AE
Fargo, ND
Hiring · 35 open roles
80.3 100.0 1 insp · 0 GMP 2024-11-08 · NAI — —
9
Oklahoma City, OK
78.6 98.2 1 insp · 0 GMP 2026-06-17 · VAI Available —
10
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
11
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
12
BM
Vienna, Austria
76.8 100.0 0 insp · 12 GMP None on file — —
13
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
How we score CDMOs →

What to evaluate in a Plasmid DNA CDMO

GMP grade & purity
Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.
Fermentation scale & yield
Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.
Lead time
Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Plasmid DNA CDMOs — Frequently Asked Questions

How many Plasmid DNA CDMOs have FDA inspection records?
CDMO Signal tracks 9 Plasmid DNA CDMOs with FDA inspection records and 78 EMA/MHRA GMP certificates across the group.
What should I look for in a plasmid DNA CDMO?
Confirm GMP grade and purity specs (supercoiled %, residual host DNA, endotoxin), fermentation scale and yield for your demand, realistic lead time, and a clean FDA and EMA/MHRA record.
Why is plasmid DNA supply often a bottleneck?
Plasmid is the starting material for viral vectors and mRNA, so a single GMP plasmid lot gates multiple downstream steps. Constrained GMP fermentation capacity and long queues make it a frequent critical-path item.
Related modalities
mRNA / LNP CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector